Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NeuBase Therapeutics (NBSE) stocks in Canada

Learn how to easily invest in NeuBase Therapeutics stocks.

NeuBase Therapeutics is a biotechnology business based in the US. NeuBase Therapeutics stocks (NBSE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.76 – a decrease of 3.44% over the previous week. NeuBase Therapeutics employs 33 staff and has a market cap (total outstanding stock value) of $32.3 million.

How to buy stocks in NeuBase Therapeutics

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NBSE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

NeuBase Therapeutics stock price (NASDAQ:NBSE)

Use our graph to track the performance of NBSE stocks over time.

NeuBase Therapeutics shares at a glance

Information last updated 2022-05-20.
Latest market close$0.97
52-week range$0.89 - $5.51
50-day moving average $1.49
200-day moving average $2.56
Wall St. target price$13.25
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.04

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy NeuBase Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

NeuBase Therapeutics price performance over time

Historical closes compared with the close of $0.9656 from 2022-05-25

1 week (2022-05-17) -6.25%
1 month (2022-04-23) N/A
3 months (2022-02-23) N/A
6 months (2021-11-26) -68.85%
1 year (2021-05-27) -81.82%
2 years (2020-05-27) -87.84%
3 years (2019-05-24) 3.04
5 years (2017-05-26) 55.74%

NeuBase Therapeutics financials

Gross profit TTM $0
Return on assets TTM -54.47%
Return on equity TTM -107.81%
Profit margin 0%
Book value $1.18
Market capitalisation $32.3 million

TTM: trailing 12 months

NeuBase Therapeutics share dividends

We're not expecting NeuBase Therapeutics to pay a dividend over the next 12 months.

Have NeuBase Therapeutics's shares ever split?

NeuBase Therapeutics's shares were split on a 1:20 basis on 4 February 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeuBase Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NeuBase Therapeutics shares which in turn could have impacted NeuBase Therapeutics's share price.

NeuBase Therapeutics share price volatility

Over the last 12 months, NeuBase Therapeutics's shares have ranged in value from as little as $0.89 up to $5.51. A popular way to gauge a stock's volatility is its "beta".

NBSE.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeuBase Therapeutics's is 0.7655. This would suggest that NeuBase Therapeutics's shares are less volatile than average (for this exchange).

NeuBase Therapeutics overview

NeuBase Therapeutics, Inc. , a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site